Rosa Barrio
CIC bioGUNE, Spain
Rosa Barrio started her work on ubiquitin-like genes during her PhD at the Center of Molecular Biology Severo Ochoa (Madrid, Spain), where she characterized the ubiquitin genes in Drosophila. She continued with her studies at Harvard University-USA, IMBB-Greece, EMBL-Germany, CBMSO-Spain. She is currently Principal Investigator at the Functional Genomics Unit of CIC bioGUNE. Rosa Barrio coordinated two European projects, one of them dedicated to the training of early stage researchers (ITN program, UPStream); the other grant being a large consortium of European groups interested in the field of the ubiquitin-likes (COST, PROTEOSTASIS).
Rosa Barrio started her work on ubiquitin-like genes during her PhD at the Center of Molecular Biology Severo Ochoa (Madrid, Spain), where she characterized the ubiquitin genes in Drosophila. She continued with her studies at Harvard University-USA, IMBB-Greece, EMBL-Germany, CBMSO-Spain. She is currently Principal Investigator at the Functional Genomics Unit of CIC bioGUNE. Rosa Barrio coordinated two European projects, one of them dedicated to the training of early stage researchers (ITN program, UPStream); the other grant being a large consortium of European groups interested in the field of the ubiquitin-likes (COST, PROTEOSTASIS).
Sylvie Urbé
University of Liverpool, UK
Sylvie Urbé was born and educated in Luxembourg, studied Biology at the University of Heidelberg and worked at the European Molecular Biology Laboratory on vesicular traffic and Rab GTPases. She was awarded a PhD from University College London for her study of the regulated secretory pathway in neuroendocrine cells at the Imperial Cancer Research Fund in London. Her post-doctoral work was focussed on endosomal sorting (ESCRT, HGS/HRS) and led on to a series of Wellcome Trust and Cancer Research UK funded Fellowships supporting her work on the regulation of receptor trafficking and signalling by deubiquitylases (DUBs). She now holds a professorial chair at the University of Liverpool, where she works closely together with Michael Clague, studying the cell biology of this family of enzymes and exploring their potential as therapeutic drug targets.
Sylvie Urbé was born and educated in Luxembourg, studied Biology at the University of Heidelberg and worked at the European Molecular Biology Laboratory on vesicular traffic and Rab GTPases. She was awarded a PhD from University College London for her study of the regulated secretory pathway in neuroendocrine cells at the Imperial Cancer Research Fund in London. Her post-doctoral work was focussed on endosomal sorting (ESCRT, HGS/HRS) and led on to a series of Wellcome Trust and Cancer Research UK funded Fellowships supporting her work on the regulation of receptor trafficking and signalling by deubiquitylases (DUBs). She now holds a professorial chair at the University of Liverpool, where she works closely together with Michael Clague, studying the cell biology of this family of enzymes and exploring their potential as therapeutic drug targets.
Andrea Pichler
Max Planck Institute of Immunobiology and Epigenetics, Germany
Andrea Pichler, Ph.D., is a group leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany. She graduated in Molecular Biology from the University of Vienna in 1998 and did her first postdoc at the Novartis Research Institute in Vienna. In 2000 she moved to the Max Planck Institute of Biochemistry in Munich and started in Frauke Melchior´s lab her work on sumoylation. In 2006 she returned back to Vienna establishing her own group at the Max F. Perutz Laboratories mainly focusing on E2 regulation via sumoylation. Since 2010 she is back in Germany and her lab aims to understand how SUMO conjugation is regulated via E3 ligases and Ubc9 sumoylation. Recent work of her lab identified and characterized a novel class of SUMO E3 ligases, the ZNF451 family.
Andrea Pichler, Ph.D., is a group leader at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany. She graduated in Molecular Biology from the University of Vienna in 1998 and did her first postdoc at the Novartis Research Institute in Vienna. In 2000 she moved to the Max Planck Institute of Biochemistry in Munich and started in Frauke Melchior´s lab her work on sumoylation. In 2006 she returned back to Vienna establishing her own group at the Max F. Perutz Laboratories mainly focusing on E2 regulation via sumoylation. Since 2010 she is back in Germany and her lab aims to understand how SUMO conjugation is regulated via E3 ligases and Ubc9 sumoylation. Recent work of her lab identified and characterized a novel class of SUMO E3 ligases, the ZNF451 family.
Huib Ovaa
Leiden University Medical Centre, Netherlands
Huib Ovaa works in the development of tools to profile the action of cellular enzymatic activities associated with cancer and infection and therapeutic intervention. This includes enzymes regulating ubiquitin family members. He obtained his PhD at Leiden University and a postdoctoral at Harvard University. He was working as Principal investigator at Netherlands Cancer Institute (NKI) and currently he leads a group at Leiden University Medical Centre. He was awarded Dana Farber Cancer Institute career development award Dutch society for biochemistry and molecular biology (NVBMB) in 2008 and 2009 respectively.
Huib Ovaa works in the development of tools to profile the action of cellular enzymatic activities associated with cancer and infection and therapeutic intervention. This includes enzymes regulating ubiquitin family members. He obtained his PhD at Leiden University and a postdoctoral at Harvard University. He was working as Principal investigator at Netherlands Cancer Institute (NKI) and currently he leads a group at Leiden University Medical Centre. He was awarded Dana Farber Cancer Institute career development award Dutch society for biochemistry and molecular biology (NVBMB) in 2008 and 2009 respectively.